Clinical Trial

Psilocybin-Assisted Therapy for Intergenerational Trauma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-21; most recent amendment 2025-09-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT06899165
Lead Sponsor Rachel Yehuda
Conditions Psychological Stress, Depression, Anxiety
Enrollment 100 participants
Start Date 2026-08-28
Primary Completion 2029-05-31 (estimated)
Study Completion 2030-01-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-13